ViroGates Reports Interim Results for Q1-Q3 2026

ViroGates reported revenue of DKK 6.2 million for the first nine months of 2026, up 75% year over year, largely due to a minimum-order delivery from U.S. partner suPARbio in Q2; Q3 revenue was DKK 1.1 million. The company maintained its full-year guidance of DKK 6.5–8 million in revenue and an EBIT loss of DKK 10–12 million. ViroGates is shifting from a sales-driven model toward business development focused on larger, scalable partnerships, reviewing its partner portfolio and planning to replace its “recurring customers” KPI with revenue reporting by product and geography from 2027.